Nexentis Technologies Inc.

11/16/2026 | Press release | Distributed by Public on 11/16/2026 08:01

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes included elsewhere in this Quarterly Report. In addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See "Forward-Looking Statements" for a discussion of the uncertainties and assumptions associated with these statements. Our actual results may differ materially from those discussed below.

All information in this Quarterly Report relating to shares or price per share reflects the 1-for-35 reverse stock split effected by us on September 22, 2025 and the 1-for-7 reverse stock split effected by us on April 8, 2026 and the 1-for-5 reverse stock split effected by us on November 9, 2026.

Overview

We are focused on sustainable operations in various industries such as oncology biotechnology and solar projects. Our activities are advancing innovative oncology solutions through MitoCareX to improve cancer treatment outcomes.

We currently operate through our wholly owned Israeli subsidiary and our Nevada wholly-owned subsidiary and collaborate and invest in a joint venture in the solar energy sector:

MitoCareX, which has been our wholly owned subsidiary since October 2025, develops and advances targeted therapeutics for diverse types of indications by focusing on transport proteins (i.e., transporters). MitoCareX develops technologies that are designed to interact with transporters, thereby potentially disrupting the disease. MitoCareX routinely utilizes structural biology in combination with computational chemistry to discover, design and develop drug candidates that interact with its protein targets of interest. MitoCareX's approach leverages a proprietary MITOLINEā„¢ algorithm, which enables the reliable generation of 3D molecular structural models of MitoCareX's protein targets and allows for large-scale virtual screening campaigns against these targets. MITOLINEā„¢ provides a platform-level starting point to enable modelling and further allows to discover potential therapeutics. A key advantage of MitoCareX platform is its ability to address the historical lack of experimental structural data that has limited drug discovery efforts targeting MitoCareX's proteins of interest, thereby potentially expanding the druggable target space. By enabling rational, structure-guided discovery at scale, MitoCareX's solutions are designed to unlock new treatment opportunities. Recently, MitoCareX entered into an engagement with Boltz, PBC ("Boltz"), an AI research lab that focuses on biomolecular foundation models and drug discovery workflows, to accelerate the identification of potential therapeutics targeting selected proteins of interest to MitoCareX's pipeline. In October 2026, MitoCareX completed an initial computational screening stage under this initiative.

We collaborate with Solterra Renewable Energy Ltd., an Israeli corporation ("Solterra") and a former wholly-owned subsidiary of Solterra Energy Ltd., an Israeli public corporation, listed on the Tel Aviv Stock Exchange ("Solterra Energy"), which operates in the solar energy sector and presents certain investment opportunities in solar photovoltaic ("PV") projects. Solterra engages in the development of renewable energy projects through its subsidiaries. Currently, operations are conducted in Italy, Poland, and Germany, with potential expansion to additional countries. Our subsidiary, NITO Renewable, was established in February 2025 in the State of Nevada and has a 70% interest in the joint venture in Italy. Solterra's business strategy primarily involves selling renewable energy projects to third parties at various stages of development, from the initial land identification and project advancement through construction, operation, or sale to a third party. Currently, most projects are expected to be sold at various development stages, with the possibility of a larger portion of projects being held long-term for operation by Solterra in the future. In July 2026, Solterra Energy completed the sale of 100% of the issued share capital of Solterra to Sunflower Sustainable Investments Ltd., an Israeli public corporation listed on the Tel Aviv Stock Exchange. We currently intend to continue to collaborate with Solterra as Solterra surveys the European solar energy market for additional projects.

During 2025, the Company underwent significant changes to its business operations. In April 2025, the Company completed the sale of its NTWO OFF Ltd. operations. In addition, during 2025, the Company classified the operations of Save Foods Ltd., our former 98.48% owned subsidiary ("Save Foods"), as held for sale and discontinued operations. Accordingly, the results of these operations are presented separately in the consolidated financial statements and are not included in the discussion of continuing operations below.

As a result of these changes, the Company's consolidated financial statements for the periods presented have been reclassified to conform to the current presentation, and therefore may not be directly comparable to prior periods. Unless otherwise indicated, the discussion below relates to the Company's continuing operations.

On January 13, 2026, we entered into a Securities Exchange Agreement (the "SF Agreement") with Voice Assist, Inc., a public company incorporated under the laws of the State of Nevada ("Voice Assist"), and, for certain limited purposes set forth therein, Save Foods. On January 13, 2026, we also entered into a Services Agreement with Voice Assist (the "Services Agreement"), pursuant to which we will provide non-exclusive general advisory, support, collaboration and related services to Voice Assist from time to time for consideration consisting of deferred cash from future Voice Assist financings (subject to a $1,000,000 cap), royalty consideration on "New Future Projects" (as defined in the Services Agreement) over specified periods, and a share of any "Ecolab Gross Proceeds" (as defined in the Services Agreement) related to the Ecolab Claim, and the Services Agreement includes successor obligations with respect to royalty consideration and a term through calendar year 2026 with the Company's extension rights until consideration is fully received. On March 15, 2026, we closed the SF Agreement (the "Closing"). At the Closing, we transferred to Voice Assist all of the ordinary shares of Save Foods owned by us, representing approximately 98% of the issued and outstanding ordinary share capital of Save Foods, free and clear of any encumbrances and Voice Assist delivered to us number of shares of common stock of Voice Assist, par value $0.001 per share, that represented 19.99% of Voice Assist shares of common stock.

We currently own 19.99% of Voice Assist.

Additionally, we currently own approximately 8.2% of Plantify Foods Inc. ("Plantify"), a Canadian-based public company listed on the TSX Venture Exchange that was previously engaged in the food tech industry primarily through its Israeli subsidiary, Piece of Bean Ltd. ("Piece of Bean"), which was involved in the production and distribution of clean label food. Piece of Bean's factory and business operations, located in Kibbutz Gonen in the Golan Heights, were severely impacted by the recent war in Israel, and Piece of Bean is in the process of voluntary insolvency proceedings. As a consequence, Plantify currently has essentially no business activity and minimal liquidity.

Recent Developments

Nasdaq Listing Compliance

On August 31, 2026, we received a letter (the "Letter") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying us that our stockholders' equity of $1,782,000, as reported in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, was below the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain stockholders' equity of at least $2,500,000. The Letter had no immediate impact on the listing or trading of our common stock on The Nasdaq Capital Market. Pursuant to the Letter, we had 45 calendar days, or until October 15, 2026, to submit a plan to regain compliance and, if such plan is accepted, the Listing Qualifications Staff may grant an extension of up to 180 calendar days from the date of the Letter, or through February 27, 2027, to evidence compliance. On October 10, 2026, we submitted a plan to regain compliance to the Listing Qualifications Staff.

On September 29, 2026, we entered into amendment agreements (the "Amendment Agreements") with the holders of all outstanding warrants issued in connection with (i) our credit facility with L.I.A. Pure Capital Ltd., originally entered into on October 1, 2024 and amended and restated in May 2026, (ii) our concurrent private placement conducted alongside our registered direct offering that closed on June 15, 2026 and (iii) our concurrent private placement conducted alongside our registered direct offering that closed on June 24, 2026 (collectively, the "Existing Warrants"). Pursuant to the Amendment Agreements, the parties agreed to amend the Existing Warrants and enter into amended and restated warrants (the "Amended Warrants" and, together with the Amendment Agreements, the "Amendments"). The Amended Warrants removed certain provisions contained in the Existing Warrants that resulted in liability classification for accounting purposes, and we determined that the Amended Warrants qualify for equity classification under applicable accounting guidance. The Amendments did not increase the number of shares issuable upon exercise of the Existing Warrants, extend their terms or otherwise provide additional economic consideration to the holders thereof, and were effected in connection with our efforts to regain compliance with Nasdaq Listing Rule 5550(b)(1). As a result of the Amendments and the non-cash financing income recognized during the third quarter of 2026, our reported stockholders' equity as of September 30, 2026 was $12,774,000, which exceeded the minimum requirement of $2,500,000. However, Nasdaq will continue to monitor our compliance with the stockholders' equity requirement, and there can be no assurance that Nasdaq will determine that we have regained compliance, that we will be able to maintain compliance with Nasdaq Listing Rule 5550(b)(1) or any other continued listing requirement, or that our common stock will not be delisted.

Subsequent Equity Issuances and Warrant Exercises

On October 7, 2026, we issued 110,337 shares of common stock upon the exercise of outstanding warrants.

On October 15, 2026, we issued an aggregate of 184,438 shares of common stock to our directors, executive officers and consultants in consideration of services provided to the Company. Of these shares, 82,438 were issued pursuant to the Company's 2022 Share Incentive Plan to our Chief Executive Officer, our Chief Financial Officer, our directors and a consultant, while the remaining 102,000 shares were issued to consultants outside the plan for financial, investor relations and business development services.

On October 26, 2026, we issued an additional 2,000 shares of common stock to a consultant in consideration of services provided to the Company.

2026 Annual Meeting and Proposed Convertible Note Financing Facility

On November 9, 2026, we filed a preliminary proxy statement with the SEC for our 2026 annual meeting of stockholders, scheduled to be held on December 30, 2026, at which our stockholders will be asked, among other things, to approve, for purposes of Nasdaq Listing Rule 5635(d), (i) the issuance of up to 20,000,000 shares of common stock (subject to adjustment for any reverse stock split effected prior to such offerings), for aggregate consideration of up to $100 million, in one or more non-public offerings at a maximum discount of 20% below the market price of our common stock, and (ii) the potential issuance of shares of common stock pursuant to a proposed convertible note financing facility with a single investor, under which we may issue unsecured convertible promissory notes in an aggregate principal amount of up to $10 million, together with warrants and shares issuable as a commitment fee.

We have negotiated with a single investor (the "Investor") the material terms of a proposed convertible note financing facility. We and the Investor have not yet entered into definitive agreements with respect to the proposed financing. We presently intend to enter into definitive agreements with the Investor following receipt of the stockholder approval sought pursuant to this Proposal, substantially on the terms described below. The proposed definitive agreements are expected to consist of a Securities Purchase Agreement (the "Purchase Agreement"), unsecured convertible promissory notes to be issued thereunder (the "Notes") and warrants to purchase shares of our common stock to be issued in connection with each Note (the "Warrants," and together with the Purchase Agreement and the Notes, the "Transaction Documents"). The shares of common stock issuable upon conversion of the Notes are referred to as the "Conversion Shares," the shares of common stock issuable upon exercise of the Warrants are referred to as the "Warrant Shares," and the shares of common stock proposed to be issued as a commitment fee are referred to as the "Commitment Shares."

Under the proposed Purchase Agreement, we would be permitted to issue and sell to the Investor, from time to time, Notes in an aggregate principal amount of up to $10 million. Upon execution of the Purchase Agreement (the "Initial Closing"), the Investor would purchase from us a Note in the principal amount of $1,500,000 for a purchase price of $1,350,000. Commencing on January 1, 2027, we would be permitted to request, in our sole discretion, that the Investor purchase additional Notes, with the aggregate principal amount of Notes issued during each calendar quarter not to exceed $1,500,000. Each Note would be issued at a purchase price equal to 90% of its principal amount, reflecting a 10% original issue discount.

Each Note would mature 28 months after its issuance date and would bear interest at an annual rate of 8%, which would increase to 14% upon an event of default for so long as the event remains uncured. The principal amount of each Note, together with accrued and unpaid interest, would be payable in 10 equal monthly installments beginning on the first day of each month following the 18-month anniversary of the applicable issuance date, unless repaid earlier in accordance with the Note or the maturity date is extended at the option of the Investor.

The outstanding amounts due under each Note would be convertible into shares of our common stock at the option of the Investor at any time after the issuance date of the Note at a conversion price per share equal to the lower of (i) the closing price of our common stock on the trading day immediately preceding the date on which our stockholders approve this Proposal (the "Fixed Price"), and (ii) 88% of the lowest daily volume-weighted average price of our common stock during the 20 consecutive trading days immediately preceding the applicable conversion date, provided that the variable conversion price per share may not be lower than 20% of the Fixed Price (the "Floor Price"), subject to certain adjustments as provided in the Note. The Investor's right to convert a Note would be subject to the limitation that a conversion may not result in the Investor and its affiliates beneficially owning more than 4.99% of our outstanding common stock.

At each closing under the Purchase Agreement, we would also issue to the Investor a Warrant to purchase a number of shares of common stock equal to 100% of the Conversion Shares underlying the Note issued at that closing, determined by dividing the principal amount of the applicable Note by the variable conversion price then in effect. Each Warrant would have an exercise price per share equal to 80% of the Fixed Price and would expire 60 months after issuance, in each case subject to adjustment as provided in the Warrant. The Investor's right to exercise a Warrant would also be subject to a 4.99% beneficial ownership limitation.

In consideration for the Investor's execution and delivery of the Purchase Agreement, at the Initial Closing we would issue to the Investor a number of Commitment Shares equal to 4.99% of the number of shares of our common stock outstanding immediately after giving effect to such issuance.

Under the proposed Purchase Agreement, we would be required to prepare and file with the Securities and Exchange Commission, as soon as practicable but no later than 30 trading days after execution of the Purchase Agreement, a resale registration statement covering the Conversion Shares, the Warrant Shares and the Commitment Shares, and to use reasonable best efforts to cause the registration statement to become effective within the period specified in the Purchase Agreement.

If a Nasdaq rule establishing a minimum Market Value of Listed Securities requirement of at least $5.0 million for companies listed on the Nasdaq Capital Market becomes effective while any portion of a Note remains outstanding, from and after the effectiveness of such rule, the conversion price under the Notes would be equal to the lower of (i) the Fixed Price and (ii) 50% of the lowest daily volume-weighted average price of our common stock during the 20 consecutive trading days immediately preceding the applicable conversion date, subject to the Floor Price.

Because definitive agreements have not yet been executed, there can be no assurance that the proposed financing will be consummated. If definitive agreements are executed, we expect that the material terms of the financing will be substantially as described in this Proposal. If definitive agreements are executed, the foregoing descriptions will be qualified in their entirety by reference to the full text of the Transaction Documents, which we expect to file with the SEC as required by applicable law.

In addition to the proposals described above, at the 2026 annual meeting, our stockholders will also be asked, among other things, to approve an amendment to our 2022 Share Incentive Plan to increase the number of shares of common stock available for issuance thereunder by an additional 1,000,000 shares of common stock.

Results of Operations

The 2025 comparative amounts presented below have been recast to reflect the classification of the Company's Save Foods and NTWO OFF Ltd. operations as discontinued operations. Accordingly, the results of these discontinued operations are excluded from continuing operations. Unless otherwise indicated, the discussion below relates only to the Company's continuing operations.

Operating Expenses

Our current operating expenses consist of five components - research and development expenses, general and administrative expenses, change in fair value of contingent consideration, goodwill impairment and depreciation and amortization.

Research and Development Expenses

Our research and development expenses consist primarily of salaries and related expenses and other related research and development expenses such as field tests.

Nine Months Ended

September 30,

Three Months Ended

September 30,

U.S. dollars 2026 2025 2026 2025
Salaries and related expenses 599,000 - 174,000 -
Subcontractors 67,000 - 20,000 -
Laboratory and Field tests 178,000 - 61,000 -
Other expenses 92,000 - 33,000 -
Total 936,000 - 288,000 -

General and Administrative Expenses

General and administrative expenses consist primarily of professional services, share based compensation and other non-personnel related expenses.

Nine Months Ended

September 30,

Three Months Ended

September 30,

U.S. dollars 2026 2025 2026 2025
Professional services 1,763,000 1,645,000 429,000 777,000
Share based compensation 1,828,000 2,141,000 429,000 112,000
Salaries and related expenses 115,000 - 19,000 -
Legal expenses 231,000 233,000 36,000 130,000
Insurance 94,000 106,000 32,000 32,000
Registration fees 54,000 61,000 15,000 18,000
Other expenses 56,000 15,000 25,000 2,000
Total 4,141,000 4,201,000 985,000 1,071,000

Three months ended September 30, 2026 compared to three months ended September 30, 2025

Research and Development Expenses

Research and development expenses consist of salaries and related expenses, service providers' costs, related materials and overhead expenses. Research and development expenses for the three months ended September 30, 2026 were $288,000, compared to no research and development expenses for the three months ended September 30, 2025. The increase was attributable to research and development activities following the acquisition of MitoCareX in October 2025, including personnel-related expenses and costs associated with its ongoing development programs.

General and Administrative Expenses

General and administrative expenses consisted primarily of professional services, salaries and related expenses including share based compensation and other non-personnel related expenses, including legal expenses and directors and officers insurance costs. General and administrative expenses for the three months ended September 30, 2026 were $985,000, a decrease of $86,000, or 8%, compared to general and administrative expenses of $1,071,000 for the three months ended September 30, 2025. The decrease was primarily attributable to decrease of professional services and legal expenses, partially offset by an increase of share-based compensation to our employees and service providers.

Change in fair value of contingent consideration

Change in fair value of contingent consideration for the three months ended September 30, 2026 resulted in a non-cash gain of $146,000. The contingent equity consideration was recognized in connection with the acquisition of MitoCareX in October 2025 and is remeasured at fair value at each reporting date, with changes in fair value recognized in the statement of operations. The gain was primarily attributable to a decrease in the market price of the Company's common stock during the period, which reduced the fair value of the liability associated with the contingent equity consideration.

Depreciation and amortization

Depreciation and amortization for the three months ended September 30, 2026 was $107,000, compared to no depreciation and amortization for the three months ended September 30, 2025. The increase was attributable to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX in October 2025 as part of the purchase price allocation.

Financing income, Net

Financing income, net for the three months ended September 30, 2026 was $7,067,000, an increase of $6,893,000 or 3,961%, compared to financing income, net of $174,000 for the three months ended September 30, 2025. The increase was primarily attributable to non-cash gains resulting from decreases in the fair value of the warrant liabilities associated with our credit facility with L.I.A. Pure Capital Ltd. and the warrants issued in the concurrent private placements that closed in June 2026, primarily due to a decrease in the market price of our common stock during the period. On September 29, 2026, we amended these warrants and, following their final remeasurement to fair value, the warrants were reclassified from liabilities to equity.

Income taxes

Income tax benefit for the three months ended September 30, 2026 was $24,000. The tax benefit is primarily attributable to a reduction in deferred tax liabilities, and does not reflect taxable income generated from operations. The decrease in deferred tax liabilities was primarily related to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX, which resulted in a corresponding income tax benefit.

Net gain from continuing operations

Net gain from continuing operations for the three months ended September 30, 2026, was $5,002,000, compared to $616,000 for the three months ended September 30, 2025, an increase of $4,386,000, or 712%. The increase was primarily attributable to higher financing income, net, as discussed above.

Net gain (loss) from discontinued operations

Net gain from discontinued operations for the three months ended September 30, 2026, was $17,000, compared to a net loss of $246,000 for the three months ended September 30, 2025. The gain in 2026 resulted from a post-closing adjustment related to the reconciliation of outstanding balances following the sale of Save Foods Ltd. in March 2026. The loss in 2025 reflected the operating results of the former Save Foods business.

Total net gain

As a result of the foregoing, our total net gain for the three months ended September 30, 2026 was $5,019,000 compared to $370,000 for the three months ended September 30, 2025, an increase of $4,649,000, or 1,256%.

Nine months ended September 30, 2026 compared to nine months ended September 30, 2025

Research and Development Expenses

Research and development expenses consist of salaries and related expenses, service providers' costs, related materials and overhead expenses. Research and development expenses for the nine months ended September 30, 2026 were $936,000, compared to no research and development expenses for the nine months ended September 30, 2025. The increase was attributable to research and development activities following the acquisition of MitoCareX in October 2025, including personnel-related expenses and costs associated with its ongoing development programs.

General and Administrative Expenses

General and administrative expenses consisted primarily of professional services, salaries and related expenses including share-based compensation and other non-personnel related expenses, including legal expenses and directors and officers insurance costs. General and administrative expenses for the nine months ended September 30, 2026 were $4,141,000, a decrease of $60,000, or 1%, compared to general and administrative expenses of $4,201,000 for the nine months ended September 30, 2025. The decrease was primarily attributable to decrease of share-based compensation to our employees and service providers and insurance costs , partially offset by an increase of professional services and salaries and related expenses.

Change in fair value of contingent consideration

Change in fair value of contingent consideration for the nine months ended September 30, 2026 was a gain of $349,000. The gain is related to the contingent cash and equity consideration recognized in connection with the acquisition of MitoCareX in October 2025. Following the Company's financing activities, the contingent cash consideration became fixed and payable and, following its final fair value remeasurement, was reclassified to accrued expenses. The gain reflects the combined effect of changes in the fair value of the contingent cash and equity consideration during the period, including a decrease in the fair value of the contingent equity consideration resulting from a decline in the market price of the Company's common stock. The remaining contingent equity consideration remains contingent and continues to be measured at fair value at each reporting date.

Goodwill impairment

Goodwill impairment expenses consisted of a non-cash impairment loss of $6.3 million recognized in connection with the goodwill related to the MitoCareX reporting unit during the nine months ended September 30, 2026. The impairment loss was recognized following the Company's interim goodwill impairment assessment performed during the first quarter of 2026, which was triggered by impairment indicators, including a sustained decline in the Company's share price and market capitalization. Based on the assessment, the carrying amount of the MitoCareX reporting unit exceeded its estimated fair value. The impairment charge did not impact the Company's cash flows or liquidity.

Depreciation and amortization

Depreciation and amortization for the nine months ended September 30, 2026 was $316,000, compared to no depreciation and amortization for the nine months ended September 30, 2025. The increase was attributable to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX in October 2025 as part of the purchase price allocation.

Financing expenses, Net

Financing expenses, net for the nine months ended September 30, 2026 was $1,870,000, an increase of $15,000 or 1%, compared to financing expenses, net of $1,855,000 for the nine months ended September 30, 2025. Financing expenses, net for the 2026 period reflect non-cash losses recognized during the first half of 2026 from changes in the fair value of the warrant liabilities associated with the amendment and restatement of our credit facility with L.I.A. Pure Capital Ltd. and the day-one losses recognized upon the issuance of the warrants in the June 2026 private placements, as well as higher interest expenses on outstanding loans and unfavorable foreign currency exchange differences, substantially offset by non-cash gains resulting from decreases in the fair value of such warrant liabilities during the third quarter of 2026. On September 29, 2026, we amended these warrants and, following their final remeasurement to fair value, the warrants were reclassified from liabilities to equity.

Income taxes

Income tax benefit for the nine months ended September 30, 2026 was $70,000. The tax benefit is primarily attributable to a reduction in deferred tax liabilities, and does not reflect taxable income generated from operations. The decrease in deferred tax liabilities was primarily related to the amortization of intangible assets recognized in connection with the acquisition of MitoCareX, which resulted in a corresponding income tax benefit.

Net Loss from continuing operations

Net loss from continuing operations for the nine months ended September 30, 2026, was $13,581,000, compared to $4,887,000 for the nine months ended September 30, 2025, an increase of $8,694,000, or 178%. The increase in net loss from continued operations was primarily attributable to the recognition of a non-cash goodwill impairment loss, as discussed above.

Net gain (loss) from discontinued operations

Net gain from discontinued operations for the nine months ended September 30, 2026 was $851,000, compared to net loss from discontinued operations $508,000 for the nine months ended September 30, 2025 an increase of $1,359,000, or 268%. The increase was primarily attributable to the sale of the Company's former Save Foods business through a share exchange transaction, which resulted in the elimination of the Company's negative investment balance in such business. The net loss in the 2025 period related to the operating results of the former Save Foods business, which was classified as discontinued operations during 2025.

Total net loss

As a result of the foregoing, our total net loss for the nine months ended September 30, 2026 was $12,730,000 compared to $5,395,000 for the nine months ended September 30, 2025, an increase of $7,335,000, or 136%.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures. Since our inception through September 30, 2026, we have funded our operations, principally with the issuance of equity and debt.

As of September 30, 2026, we had cash and cash equivalents of $2,837,000, as compared to $6,044,000 as of September 30, 2025. As of September 30, 2026, we had a working capital of $5,679,000, as compared to $6,598,000 as of September 30, 2025. The decrease in our cash balance is mainly attributable to cash provided by financing activities offset by cash used in operations and cash used in investing activities.

On July 23, 2023, we entered into a standby equity purchase agreement with YA II PN, Ltd. (the "Investor"), pursuant to which the Investor agreed to purchase up to $3,500,000 of shares of our common stock for 40 months from the date of the purchase agreement at a price per share equal to 94% of the lowest volume-weighted average price ("VWAP") of the common stock for the three days prior to the delivery of each advance notice from us, subject to certain limitations, including that the Investor cannot purchase a number of shares that would result in it beneficially owning more than 4.99% of our outstanding shares of common stock. In December 2023, we completed an investment round in the aggregate amount of $3,500,000.

On December 22, 2023, we entered into an additional standby equity purchase agreement with the Investor, pursuant to which the Investor has agreed to purchase up to $20 million of shares of our common stock for 36 months from the date of the purchase agreement at a price per share equal to 94% of the lowest VWAP of our common stock for the three trading days immediately following the delivery of each advance notice from us. The agreement will terminate automatically on the earlier of January 1, 2027, or when the Investor has purchased an aggregate of $20 million of our shares of common stock. We have the right to terminate the purchase agreement upon five trading days' prior written notice to the Investor. We have sold 5,457 shares of common stock at an average purchase price of $602.45 to the Investor.

In connection with and subject to the satisfaction of certain conditions set forth in the purchase agreement, upon our request, the Investor pre-advanced to us up to $3,000,000 of the $20,000,000 commitment amount (a "Pre-Advance"), with each Pre-Advance to be evidenced by a promissory note (each, a "Note"). The Pre-Advance made to us will be subject to a 3% discount to the principal amount equal to each Note. Each Note accrues interest on the outstanding principal balance at the rate of 8% per annum. The Company is required to pay, on a monthly basis, one tenth of the outstanding principal amount of each Note, together with accrued and unpaid interest, either (i) in cash or (ii) by submitting an Advance notice pursuant to the purchase agreement and selling the Investor shares, or any combination of (i) or (ii) as determined by us. The initial repayment is due 60 days after the issuance of a Note, followed by subsequent payments due every 30 days after the previous payment. Unless otherwise agreed to by the Investor, any funds received by us pursuant to the purchase agreement for the sale of shares will first be used to satisfy any payments due under an outstanding note.

On May 12, 2025, we entered into an amendment to the standby equity purchase agreement with the Investor (the "Purchase Agreement Amendment") with respect to the balance of approximately $16 million then remaining available under the standby equity purchase agreement, pursuant to which the Investor committed to advance us an aggregate principal amount of $3,000,000.

On August 12, 2025, pursuant to the Purchase Agreement Amendment, we issued a revised promissory note in the principal amount of $1,500,000 to the Investor.

As of November 16, 2026, we have sold 56,431 shares of common stock at an average purchase price of $131.85 to the Investor.

On October 20, 2025, upon fulfillment of all remaining closing conditions set forth in the Securities Purchase and Exchange Agreement, dated February 25, 2025, as amended on May 18, 2025 and July 23, 2025, by and among the Company, MitoCareX, SciSparc Ltd., Dr. Alon Silberman and Prof. Ciro Leonardo Pierri, and as consideration thereunder, the Company remitted a cash payment in the amount of $700,000 to SciSparc Ltd.

On December 10, 2024, we entered into a securities purchase agreement with certain investors for gross proceeds of approximately $1,500,000 in a private placement. The private placement closed on January 2, 2025, at which time we issued 1,392 shares of common stock, pre-funded warrants to purchase 3,711 shares of common stock and warrants to purchase 7,654 shares of common stock.

On October 1, 2024, we entered into a facility agreement with L.I.A. Pure Capital Ltd. On May 27, 2026, following stockholder approval, we and with L.I.A. Pure Capital Ltd. released from escrow the signatures to an amended and restated facility agreement, which increased the total amount available under the credit facility from EUR 6.0 million to EUR 10.0 million. The principal economic terms of the credit facility otherwise remained substantially unchanged. On October 7, 2026, L.I.A. Pure Capital Ltd. exercised warrants issued in connection with the amended and restated facility agreement for an aggregate cash consideration of approximately $552 thousand. The exercise related to 110,337 shares of Common Stock at an exercise price of $5.00 per share. Following the exercise, the warrant remains exercisable for 259,663 shares of Common Stock. See Note 9 for additional information.

On June 12, 2026, we entered into a securities purchase agreement with certain investors for the issuance of 62,379 shares of common stock in a registered direct offering and warrants to purchase 62,379 shares of common stock in a concurrent private placement. The warrants have an exercise price of $20.04 per share. The offerings closed on June 15, 2026, and generated aggregate gross proceeds of approximately $1.25 million, before offering expenses.

On June 22, 2026, we entered into a securities purchase agreement with certain investors for the issuance of 82,204 shares of common stock in a registered direct offering and warrants to purchase 82,204 shares of common stock in a concurrent private placement. The warrants have an exercise price of $35.28 per share. The offerings closed on June 24, 2026, and generated aggregate gross proceeds of approximately $2.9 million, before offering expenses.

The table below presents our cash flows for the periods indicated:

Nine Months Ended

September 30,

2026 2025
Net cash used in operating activities (3,186,000 ) (2,311,000 )
Net cash used in investing activities (3,351,000 ) (1,898,000 )
Net cash provided by financing activities 5,376,000 8,097,000
Effect of exchange rate changes on cash and cash equivalents and restricted cash 24,000 (27,000 )
Increase (decrease) in cash and cash equivalents (1,137,000 ) 3,861,000

Going Concern

Since our incorporation, we incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. As of September 30, 2026, we had an accumulated deficit of $51,253,000, and we expect to incur losses for the foreseeable future. We have financed our operations mainly through fundraising from various investors and have limited revenue from our products and therefore are dependent upon external sources to finance our operations. There can be no assurance that we will succeed in obtaining the necessary financing to continue our operations. These factors raise substantial doubt about our ability to continue as a going concern through at least twelve months from the date of this Quarterly Report.

We believe that our existing capital resources will not be sufficient to support our operating plan during the twelve months following the date of issuance of these financial statements. We will likely seek to raise additional capital to support our growth or other strategic initiatives through the issuance of debt, equity, or a combination thereof. There can be no assurance we will be successful in raising additional capital on favorable terms, or at all.

As a result, there is substantial doubt about our ability to continue as a going concern. If we are unable to obtain sufficient amounts of additional capital, we may be required to reduce the scope of our planned development, which could harm our business, financial condition and operating results. If we obtain additional funds by selling any of our equity, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or the equity securities may have rights preferences or privileges senior to the common stock. If we issue debt securities, there may be negative covenants which may restrict our company's activities. If adequate funds are not available to our company when needed on satisfactory terms, we may be required to cease operating or otherwise modify our business strategy. The financial statements included in this Quarterly Report do not include adjustments for measurement or presentation of assets and liabilities, which may be required should we fail to operate as a going concern.

Operating Activities

Net cash used in operating activities was $3,186,000 for the nine months ended September 30, 2026, as compared to $2,311,000 for the nine months ended September 30, 2025. The increase is mainly attributable to higher cash used to fund operating activities in the nine months ended September 30, 2026, including MitoCareX's research and development activities. The increase was partially offset by decrease in prepaid expenses and other current assets, while a decrease in other liabilities increased cash used in operating activities.

Investing Activities

Net cash used in investing activities was $3,351,000 for the nine months ended September 30, 2026, as compared to net cash used in investing activities of $1,898,000 for the nine months ended September 30, 2025. The increase of $1,453,000 was primarily attributable to the investment of $3,300,000 in short-term bank deposits during the 2026 period, compared to no such investments in the corresponding 2025 period. This increase was partially offset by proceeds of $604,000 from repayments of loans related to solar photovoltaic projects, lower investments in solar projects under development and in the solar photovoltaic joint venture project, and the absence of short-term loans granted during the 2026 period, compared to $786,000 of short-term loans granted in the corresponding 2025 period. These offsetting factors were partially reduced by the purchase of property and cash outflows related to discontinued operations in the 2026 period.

Financing Activities

Net cash provided by financing activities was $5,376,000 for the nine months ended September 30, 2026, as compared to net cash provided by financing activities of $8,097,000 for the nine months ended September 30, 2025, representing a decrease of $2,721,000. During the nine months ended September 30, 2026, cash provided by financing activities primarily consisted of gross proceeds of $4,150,000 from the June 2026 private placements and net proceeds of $2,896,000 under the standby equity purchase agreement, partially offset by the repayment of a $1,200,000 promissory note and a payment of $470,000 in contingent consideration related to the MitoCareX acquisition. The decrease compared to the corresponding prior-year period was primarily attributable to the absence of proceeds from warrant exercises and promissory notes received in 2025, repayments of short-term loans in 2026, and lower net proceeds from the purchase agreement, partially offset by higher proceeds from the issuance of shares and warrants in 2026.

Nexentis Technologies Inc. published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 16, 2026 at 14:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]